I would assume if they already had a significant OS result they would be required to present it, even though it was not a prescribed end point of the study. It would quickly become the standard first line. We can dream... It would also have likely been included in the abstract if this were so. I believe it is safe to assume it is insignificant with the current data. Insignificant data will still be very interesting if they present it and it shows improvement even at a significant level.
I would love to see OS + 4.8 months with a HR>0.6 with a p<0.1, that would indicate to me a very likely scenario for a successful FOXFIRE. But this goes both ways.... my guess, they'll wait for FOXFIRE.
Thanks Cafa, it was '35% for mCRC and about 30% for HCC', therefore I would assume off label usage of 35%. Although i'm still not 100% sure on the off label uses. Is this for other cancers? RCC- Kidney cancer? Or off label early liver treatments?
Also I think I might hold off calling them for a few weeks, I can wait, ASCO can not.
6186mark, yes sales and marketing is important but I feel like Sirtex are clearly gunning to become the standard of care. Meaning oncologists must prescribe sir-spheres or risk being negligent.
SRX Price at posting:
$27.55 Sentiment: Buy Disclosure: Held
